CMS Denial Of Visudyne Coverage Would Give Physicians No Option – Society

A CMS denial of coverage for Visudyne (verteporfin) therapy for certain age-related blindness patients would have the effect of forcing physicians to conduct unethical trials, The Vitreous Society maintains in recent comments to the agency